PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2022.13422023552468-478Optimal Definition of Oligometastasis Showing Survival Benefits of Local Therapies during Tyrosine Kinase Inhibitor TreatmentYoon Jung Jang, Dong-gon Hyun, Wonjun Ji, Chang-Min Choi, Shinkyo Yoon, Dae Ho Lee, Sang-We Kim, Jae Cheol Leehttp://e-crt.org/upload/pdf/crt-2022-1342.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2022.1342, http://e-crt.org/upload/pdf/crt-2022-1342.pdf
The Oncologist10.1634/theoncologist.2020-001120202510867-877Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung CancerMohammad Jahanzeb, Huamao M. Lin, Xiaoyun Pan, Yu Yin, Yanyu Wu, Beth Nordstrom, Mark A. Socinskihttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1634%2Ftheoncologist.2020-0011, https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2020-0011, https://onlinelibrary.wiley.com/doi/full-xml/10.1634/theoncologist.2020-0011, https://academic.oup.com/oncolo/article-pdf/25/10/867/41920508/oncolo_25_10_867.pdf, https://academic.oup.com/oncolo/article-pdf/25/10/867/41920508/oncolo_25_10_867.pdf
International Journal of Urological Nursing10.1111/ijun.122682021153144-144The challenges and benefits of toxicity management for tyrosine kinase inhibitor therapies in renal cancerMichelle Greenwood, Shievon Smithhttps://onlinelibrary.wiley.com/doi/pdf/10.1111/ijun.12268, https://onlinelibrary.wiley.com/doi/full-xml/10.1111/ijun.12268, https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijun.12268
HemaSphere10.1097/01.hs9.0000969636.32603.d420237S3e32603d4P683: TRIALS IN PROGRESS: FIRST-IN-HUMAN STUDY OF ELVN-001, A SELECTIVE BCR::ABL1 TYROSINE KINASE INHIBITOR, IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA WHO FAILED PREVIOUS TYROSINE KINASE INHIBITOR THERAPIESFabian Lang, Susan Branford, Joseph P. Lyssikatos, Helen Collins, Andreas Hochhaushttps://journals.lww.com/10.1097/01.HS9.0000969636.32603.d4
Reactions Weekly10.1007/s40278-017-38741-920171679116-16Afatinib/gefitinibhttp://link.springer.com/content/pdf/10.1007/s40278-017-38741-9.pdf, http://link.springer.com/article/10.1007/s40278-017-38741-9/fulltext.html, http://link.springer.com/content/pdf/10.1007/s40278-017-38741-9.pdf
Kinase Inhibitor Drugs10.1002/9780470524961.ch120091-39Discovery and Development of Sunitinib (SU11248): A Multitarget Tyrosine Kinase Inhibitor of Tumor Growth, Survival, and AngiogenesisConnie L. Sun, James G. Christensen, Gerald McMahonhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/9780470524961.ch1
Annals of Oncology10.1093/annonc/mdm42020071891582-1583Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinibS. Boeck, A. Wollenberg, V. Heinemannhttps://api.elsevier.com/content/article/PII:S0923753419421996?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419421996?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/18/9/1582/539975/mdm420.pdf
Journal of Blood Medicine10.2147/jbm.s331422013111Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophiliaJean-Baptiste Demoulin, Violaine Havelangehttps://www.dovepress.com/getfile.php?fileID=17081
Biomedicine & Pharmacotherapy10.1016/0753-3322(92)90171-31992465-728186. Herbimycin A, an inhibitor of tyrosine kinase prolongs survival of mice inoculated with myeloid leukemia C1 cells with high expression of v-abl tyrosine kinaseY Honma, M Hozumihttps://api.elsevier.com/content/article/PII:0753332292901713?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:0753332292901713?httpAccept=text/plain
Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia10.1007/978-4-431-55714-2_4201653-67Goals of CML Treatment in the Tyrosine Kinase Inhibitor EraJerald Radich, Daniel Eganhttps://link.springer.com/content/pdf/10.1007/978-4-431-55714-2_4